Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
13.46(c) 13.43(c) 15.94(c) 17.17(c) 16.48(c) Last
8 684 724 5 817 849 12 190 348 8 632 298 2 762 452 Volume
+2.51% -0.22% +18.69% +7.72% -4.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 40,8 M - -
Net income 2021 -256 M - -
Net cash position 2021 411 M - -
P/E ratio 2021 -8,66x
Yield 2021 -
Sales 2022 2,22 M - -
Net income 2022 -351 M - -
Net cash position 2022 601 M - -
P/E ratio 2022 -6,58x
Yield 2022 -
Capitalization 2 343 M 2 343 M -
EV / Sales 2021 47,3x
EV / Sales 2022 786x
Nbr of Employees 285
Free-Float 52,1%
More Financials
Company
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and... 
More about the company
Ratings of Allogene Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ALLOGENE THERAPEUTICS, INC.
10/15SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allog..
PR
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/12ALLOGENE THERAPEUTICS : JMP Securities Adjusts Allogene Therapeutics' Price Target to $27 ..
MT
10/11ALLOGENE THERAPEUTICS : SMBC Nikko Initiates Coverage on Allogene Therapeutics With Outper..
MT
10/08AFTER HOURS WATCH LIST SCORECARD : Vxrt, agrx, allo
MT
10/08Occidental Petroleum, Chubb rise; Allogene, Oshkosh fall
AQ
10/08ALLOGENE THERAPEUTICS' : Stock Slump After FDA Clinical Hold on CAR T Cell Therapy Offers ..
MT
10/08Health Care Limping in Late Trade
MT
10/08Top Midday Decliners
MT
10/08Health Care Stocks Limping Toward Weekend
MT
10/08ALLOGENE THERAPEUTICS : Roth Capital Adjusts Allogene Therapeutics PT to $35 From $60, Mai..
MT
10/08ALLOGENE THERAPEUTICS : Shares Plunge After FDA Halts Cell Therapy Trial But Clinical Hold..
MT
10/08ALLOGENE THERAPEUTICS : Oppenheimer Adjusts Allogene Therapeutics PT to $40 From $44, Main..
MT
10/08ALLOGENE THERAPEUTICS : Price Target Cut by Oppenheimer After FDA Places Clinical Hold on ..
MT
More news
News in other languages on ALLOGENE THERAPEUTICS, INC.
10/13CELLECTIS : données précliniques à venir, le titre rebondit
10/08L'effondrement des actions d'Allogene Therapeutics après l'arrêt des essais cliniques d..
10/08Les soins de santé à la traîne dans les derniers échanges
10/08Les actions du secteur de la santé à la peine en fin de semaine
10/08Les actions d'Allogene plongent après l'arrêt par la FDA d'un essai de thérapie cellula..
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 16,48 $
Average target price 37,19 $
Spread / Average Target 126%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-34.71%2 343
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156